UL16 binding protein 2 (ULBP2) is a cell surface glycoprotein encoded by ULBP2 gene located on the chromosome 6.[1][2] ULBP2 is related to MHC class I molecules, but its gene maps outside the MHC locus.[1][2] The domain structure of ULBP2 differs significantly from those of conventional MHC class I molecules. It does not contain the α3 domain and the transmembrane segment. ULBP2 is thus composed of only the α1α2 domain which is linked to the cell membrane by the GPI anchor.[1][2] It functions as a stress-induced ligand for NKG2D receptor.[2]
References
↑ 1.01.11.2Cosman D, Müllberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, Kubin M, Chalupny NJ (Feb 2001). "ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor". Immunity. 14 (2): 123–33. doi:10.1016/S1074-7613(01)00095-4. PMID11239445.
↑ 2.02.12.22.3Radosavljevic M, Cuillerier B, Wilson MJ, Clément O, Wicker S, Gilfillan S, Beck S, Trowsdale J, Bahram S (Jan 2002). "A cluster of ten novel MHC class I related genes on human chromosome 6q24.2-q25.3". Genomics. 79 (1): 114–23. doi:10.1006/geno.2001.6673. PMID11827464.
Further reading
Cerwenka A, Lanier LL (May 2003). "NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer". Tissue Antigens. 61 (5): 335–43. doi:10.1034/j.1399-0039.2003.00070.x. PMID12753652.
Onda H, Ohkubo S, Shintani Y, Ogi K, Kikuchi K, Tanaka H, Yamamoto K, Tsuji I, Ishibashi Y, Yamada T, Kitada C, Suzuki N, Sawada H, Nishimura O, Fujino M (Jul 2001). "A novel secreted tumor antigen with a glycosylphosphatidylinositol-anchored structure ubiquitously expressed in human cancers". Biochemical and Biophysical Research Communications. 285 (2): 235–43. doi:10.1006/bbrc.2001.5149. PMID11444831.
Steinle A, Li P, Morris DL, Groh V, Lanier LL, Strong RK, Spies T (2001). "Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family". Immunogenetics. 53 (4): 279–87. doi:10.1007/s002510100325. PMID11491531.
Sutherland CL, Chalupny NJ, Schooley K, VandenBos T, Kubin M, Cosman D (Jan 2002). "UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells". Journal of Immunology. 168 (2): 671–9. doi:10.4049/jimmunol.168.2.671. PMID11777960.
Radosavljevic M, Cuillerier B, Wilson MJ, Clément O, Wicker S, Gilfillan S, Beck S, Trowsdale J, Bahram S (Jan 2002). "A cluster of ten novel MHC class I related genes on human chromosome 6q24.2-q25.3". Genomics. 79 (1): 114–23. doi:10.1006/geno.2001.6673. PMID11827464.
Rölle A, Mousavi-Jazi M, Eriksson M, Odeberg J, Söderberg-Nauclér C, Cosman D, Kärre K, Cerboni C (Jul 2003). "Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein". Journal of Immunology. 171 (2): 902–8. doi:10.4049/jimmunol.171.2.902. PMID12847260.
Rohner A, Langenkamp U, Siegler U, Kalberer CP, Wodnar-Filipowicz A (Oct 2007). "Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis". Leukemia Research. 31 (10): 1393–402. doi:10.1016/j.leukres.2007.02.020. PMID17391757.
